Form PTO 1390 (REV 5-93) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER PG3672
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/980070
INTERNATIONAL APPLICATION NO. PCT/GB00/02015	INTERNATIONAL FILING DATE 25 May 2000	PRIORITY DATE CLAIMED 29 May 1999
TITLE OF INVENTION DIAGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE		
APPLICANT(S) FOR DO/EO/US Michael Robert WEST		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1 [X] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.

2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.

3. [X] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

4. [X] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.

5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [ ] is transmitted herewith (required only if not transmitted by the International Bureau).
   b. [X] has been transmitted by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).

6. [ ] A translation of the International Application into English (35 U.S.C. 371(c)(2)).

7. [ ] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau).
   b. [X] have been transmitted by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [ ] have not been made and will not be made.

8. [ ] A translation of the amendments to the claims under PCT Article 19 (35 U.S. C. 371(c)(3)).

9. [ ] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

10. [ ] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. [X] An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.

12. [ ] An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.

13. [X] A FIRST preliminary amendment.

14. [ ] A SECOND or SUBSEQUENT preliminary amendment.

15. [X] Please amend the specification by inserting before the first line the sentence: This is a 371 of International Application PCT/GB00/02015, filed 25 May, 2000, which claims benefit from the following Great Britain Application: 9912534.6, filed 29 May 1999.

16. [ ] A substitute specification.

17. [ ] A change of power of attorney and/or address letter.

18. [x] An Abstract on a separate sheet of paper.

19. [ ] Other items or information:

US APPLICATION NO. (If known, see 37 CFR 1.5) 09/980070	INTERNATIONAL APPLICATION NO. PCT/GB00/02015	ATTORNEYS DOCKET NO. PG3672

20. [X] The following fees are submitted:	CALCULATIONS	PTO USE ONLY
Basic National Fee (37 C.F.R. 1.492(a)(1)-(5)):		
Search Report has been prepared by the EPO or JPO **$890.00**		
International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) **$710.00**		
No International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) **$740.00**		
Neither International Preliminary Examination Fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....**$1,040.00**	**$1,040.00**	
International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) and all claims satisfied provisions of PCT Article 33(2)-(4).....**$100.00**		
ENTER APPROPRIATE BASIC FEE AMOUNT =	**$1,040.00**	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	**$0.00**	

Claims	Number Filed	Number Extra	Rate		
Total claims	**26 - 20 =**	**6**	**6 x $18.00**	**$108.00**	
Independent claims	**4 - 3 =**	**1**	**1 x $84.00**	**$84.00**	
Multiple dependent claims (if applicable)			**+ $280.00**	**$280.00**	
TOTAL OF ABOVE CALCULATIONS =				**$1,512.00**	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				**$**	
SUBTOTAL =				**$1,512.00**	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +				**$**	
TOTAL NATIONAL FEE =				**$1,512.00**	
				Amount to be refunded	**$**
				charged	**$**

a. ☐ A check in the amount of $____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 19-2570 in the amount of **$1,512.00** to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570 . A duplicate copy of this sheet is enclosed.

d. ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090

SIGNATURE
Edward R. Gimmi
NAME
38,891
REGISTRATION NO.

N:\ERG\APPS\PG\PG3672\transmittal.doc

"EXPRESS MAIL CERTIFICATE"
"EXPRESS MAIL" MAILING LABEL NUMBER EL 808220 826 US
DATE OF DEPOSIT 28 November 2001

Attorney Docket No.: PG3672

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Michael Robert West	28 November 2001
International Application No.:	PCT/GB00/02015	Group Art Unit: Unknown
International File Date:	25 May 2000	Examiner: Unknown
For:	DIAGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE	

Assistant Commissioner of Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the first Office Action on the merits, the Applicants request entry of the following amendment.

In the Claims:

Please amend Claims as follows:

1. (Amended) A method of determining the severity of Chronic Obstructive Pulmonary Disease (COPD) in a patient which comprises measuring the concentration of soluble E-cadherin in a sample of the patient's urine or blood serum and determining the extent of severity by reference to a correlation graph which correlates Forced Expiratory Volume in the first second of expiration (FEV1) with soluble E-cadherin concentration.

2 (Amended) A method of according to claim 1, wherein said measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum.

3 (Amended) A method according to claim 1 wherein said measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's urine.

4. (Amended) A method according to claim 1 or 2, wherein said measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum and urine.

6. (Amended) A method according to claim 5, wherein said identifying step comprises identifying the concentration of soluble E-cadherin in a sample of the patient's blood serum.

7. (Amended) A method according to claim 5, wherein said identifying step comprises identifying the concentration of soluble E-cadherin in a sample of the patient's urine.

8. (Amended) A method according to claim 5, wherein said identifying step comprises identifying the levels of soluble E-cadherin in a sample of the patient's blood serum and urine.

10. (Amended) A method according to claim 9, wherein said monitoring step comprises monitoring the concentration of soluble E-cadherin in a sample of the patient's urine.

11. (Amended) A method according to claim 9, wherein said monitoring step comprises monitoring the concentration of soluble E-cadherin in a sample of the patient's blood serum.

12. (Amended) A method according to claim 9, wherein said monitoring step comprises monitoring the concentration of soluble E-cadherin in samples of the patient's urine and blood serum with time.

14. (Amended) A product according to claim 13, wherein said means to report the concentration of soluble E-cadherin comprises and anti-soluble E-cadherin antibody.

15. (Amended) A method according to claim 1 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

16. (Newly Added) A method according to claim 2 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

17. (Newly Added) A method according to claim 3 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

18. (Newly Added) A method according to claim 4 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

19. (Newly Added) A method according to claim 5 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

20. (Newly Added) A method according to claim 6 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

21. (Newly Added) A method according to claim 7 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

22. (Newly Added) A method according to claim 8 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

23. (Newly Added) A method according to claim 9 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

24. (Newly Added) A method according to claim 10 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

25. (Newly Added) A method according to claim 11 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

26. (Newly Added) A method according to claim 12 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

Serial No.: To Be Assigned
Group Art Unit No.: Unknown

REMARKS

If it would expedite the prosecution of this application, the Examiner is invited to confer with the Applicant's undersigned attorney.

Respectfully submitted,

Edward R. Gimmi
Attorney for Applicants
Registration No. 38,891

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090
N:\ERG\APPS\micro\50052\USNational\prelimamend.DOC

Version with markings to Show Changes Made

1. (Amended) A method of determining the severity of Chronic Obstructive Pulmonary Disease (COPD) in a patient which comprises measuring the concentration of soluble E-cadherin in a sample of the patient's urine [and/]or blood serum and determining the extent of severity by reference to a correlation graph which correlates Forced Expiratory Volume in the first second of expiration (FEV1) with soluble E-cadherin concentration.

2 (Amended) A method of according to claim 1, wherein said[comprising] measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum.

3 (Amended) A method according to claim 1, wherein said[comprising] measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's urine.

4. (Amended) A method according to claims 1 [and]or 2, wherein said[which comprises] measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum and urine.

6. (Amended) A method according to claim 5, wherein said[comprising] identifying step comprises identifying the concentration of soluble E-cadherin in a sample of the patient's blood serum.

7. (Amended) A method according to claim 5, wherein said[comprising] identifying step comprises identifying the concentration of soluble E-cadherin in a sample of the patient's urine.

8. (Amended) A method according to claim 5, wherein said[comprising] identifying step comprises identifying the levels of soluble E-cadherin in a sample of the patient's blood serum and urine.

10. (Amended) A method according to claim 9, wherein said[comprising] monitoring step comprises monitoring the concentration of soluble E-cadherin in a sample of the patient's urine.

11. (Amended) A method according to claim 9, wherein said[comprising] monitoring step comprises monitoring the concentration of soluble E-cadherin in a sample of the patient's blood serum.

12. (Amended) A method according to claim 9, wherein said[comprising] monitoring step comprises monitoring the concentration of soluble E-cadherin in samples of the patient's urine and blood serum with time.

14. (Amended) A product according to claim 13, wherein said means to report the concentration of soluble E-cadherin comprises and anti-soluble E-cadherin antibody.

15. (Amended) A method according to [any one of claims 1 to 12]claim 1 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

DIAGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

This invention relates to a novel method for prognosis of a patient with a respiratory disease, specifically chronic obstructive pulmonary disease.

Chronic obstructive pulmonary disease (COPD) is a disease characterised by chronic inflammation and irreversible airflow obstruction with a decline in the lung function parameter FEV1 that is more rapid than normal. The disease has two major aspects of pathology, namely chronic bronchitis, characterised by mucus hypersecretion from the conducting airways, and emphysema, characterised by destructive changes in the alveoli.

Currently a number of pharmaceutical substances are indicated for or have been shown to be useful in treating the symptoms of COPD, including salmeterol xinafoate, fluticasone propionate and ipratropium bromide. (2R,3R,4S,5R)-2-[6-Amino-2-(1S-hydroxymethyl-2-phenyl-ethylamino)-purin-9-yl]-5-(2-ethyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol is also of development interest in the treatment of COPD, as are tiotropium, 4-hydroxy-7-[2-[[2-[[3-(2-phenylethyoxy)propyl] sulfonyl]ethyl]amino]ethyl-2(3H)-benzothiazolone and cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylic acid. However there is considerable interest in evaluating the extent, if at all, these medicines are disease modifying i.e. affect the overall progression of the disease either in terms of symptom severity or exacerbation severity.

Additionally many of the symptoms of COPD are shared by other respiratory diseases such as asthma, bronchitis, pulmonary fibrosis and tuberculosis. Accordingly COPD is considered to be a poorly diagnosed disease and due to this fact a great number of patients are denied medicine that could be of benefit to them. In addition, there is a need for new medicines that will be more effective

than current medicines. In view of the economic impact of COPD there is considerable incentive for drug discovery in this area.

The presenting symptoms for COPD are breathlessness accompanied by a decline in FEV1. Chronic bronchitis can be diagnosed by asking the patient whether they have a "productive cough" i.e. one that yields sputum. Patients are traditionally treated with bronchodilators or steroids and examined by spirometry for reversibility of airflow obstruction. If reversibility is less than 15%, and particularly if they have a long history of smoking, then they would be classified as COPD patients.

The ATS (American Thoracic Society) criteria for diagnosing COPD are as follows:

FEV1/FVC ratio<0.7

FEV1<70% predicted, <15% reversibility to inhaled B2 agonist

PLUS:

2 week oral prednisolone trial - less than 15% reversibility in FEV1

Smoking history

Excluding alpha-1 AT deficiency (by blood test)

Non-atopic (skin tests) and no history of atopy

Stable: without exacerbation for at least 6 weeks

No history of childhood asthma

There is a need in the art to identify a reliable and straightforward indicator of the COPD disease state (for example, a surrogate marker) both in order to reliably distinguish the symptoms of COPD from those of the above mentioned respiratory diseases and to predict changes in disease severity and progression, and response to medicine, before these changes are manifest clinically.

Elevated levels of cytokeratin 19 fragments have been detected in the broncheoalveolar lavage fluid of patients with chronic inflammatory lung disease

and this observation was suggested as a marker of bronchial epithelial injury (Nakamura, H. et al., 1997: Am. J. Resp. Crit. Care Med. **155**, 1217-1221). However, no attempt was made to correlate levels of this marker with lung function (e.g. FEV1).

The inventors of the present invention have surprisingly identified a hitherto unappreciated correlation between the concentration of soluble E-cadherin in blood serum and urine in a patient and the severity of COPD as measured by a reduction in the patient's FEV1.

FEV1 is the volume of air expelled from the lungs in one second, starting from a position of maximum inspiration and with the subject making maximum effort. FEV1% is the FEV1 expressed as a percentage of the forced vital capacity (FVC). The FVC is the total volume of air expelled from the lungs from a position of maximum inspiration with the subject making maximum effort.

FEV1 may be measured using a spirometer to measure the volume of air expired in the first second of exhalation.

E-cadherin is a member of the calcium dependent adhesion molecule superfamily and is expressed in epithelia, including those of the lung, gut and skin. It has a major role in controlling epithelial intercellular adhesion since it influences the formation of all epithelial intercellular junctions. Adhesion is mediated by interaction between extracellular domains of E-cadherin dimers on adjacent cells. In the adherens junction, cadherin dimers assemble in a zipper-like manner increasing the adhesive strength. In certain epithelial hyperproliferative conditions, there is some shedding of E-cadherin extracellular domains as soluble fragments, (sE-cadherin). The concentration of sE-cadherin in the circulation has been shown to be increased in patients with certain tumours and also to correlate with the PASI score (measure of disease severity)

of psoriasis patients (Matsuyoshi, N. et al. (1995) Brit. J. Dermatol. **132**, 745-749).

Concentration of E-cadherin in the blood serum or urine may be determined using a specific ELISA. Using this assay, the inventors have shown a direct and inverse linear correlation between actual FEV1 in COPD patients (as a percentage of the predicted value of FEV1) and sE-cadherin levels in serum and urine respectively.

The results of a trial demonstrating these correlations are described in Example 1 and shown in Figures 1 and 2.

Thus the concentration of soluble E-cadherin in blood serum and urine is a molecular indicator for COPD which is capable of reporting its severity without recourse to evaluating any symptom except reduction in a patient's FEV1 .

The predicted (normal) FEV1 of a patient may be calculated by the methods determined by Morris JF et al 1971: Am Rev Resp Dis **103,** 57-67 based on given height and age. The values are influenced by age, sex and height.

A patient already diagnosed as having COPD can be assayed for disease severity at a time point by comparison of his concentration of soluble E-cadherin in blood serum or urine at that time point with the indicator of severity shown in Figures 1 and 2.

Progression of COPD disease may be evaluated by monitoring the concentration of soluble E-cadherin in blood serum or urine with time.

It will be appreciated that either the concentration of soluble E-cadherin in blood serum or urine may be measured for the prognosis, however the recordal of both measurements will be confirmatory of the prognosis. The strength of the

confirmation is emphasised by the inverse correlation between the two measurements as shown in Figures 1 and 2.

It will be appreciated that a particular and unique benefit of the invention is the ease of prognosis which may be performed requiring only a simple blood or urine sample.

Thus, according to the invention, we provide a method of determining the severity of COPD in a patient which comprises measuring the concentration of soluble E-cadherin in a sample of the patient's urine and determining the extent of severity by reference to a correlation graph such as one which correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration eg. as shown in Figure 2.

We also provide a method of determining the severity of COPD in a patient which comprises measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum and determining the extent of severity by reference to a correlation graph such as one which correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration eg. as shown in Figure 1.

For greater confidence, the method may comprise measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum and urine and determining the extent of severity by reference to a correlation graph for each such as one which correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration eg. as shown in Figures 1 and 2.

As a further aspect of the present invention we provide a method of treating a patient suffering from COPD which comprises determining the extent of the disease by identifying the levels of soluble E-cadherin in a sample of the

patient's blood serum followed by administration of a compound which ameliorates the symptoms of the disease.

We also provide a method of treating a patient suffering from COPD which comprises determining the extent of the disease by identifying the levels of soluble E-cadherin in a sample of the patient's urine followed by administration of a compound which ameliorates the symptoms of the disease.

We also provide a method of treating a patient suffering from COPD which comprises determining the extent of the disease by identifying the levels of soluble E-cadherin in a sample of the patient's blood serum and urine followed by administration of a compound which ameliorates the symptoms of the disease.

As a further aspect of the invention we provide a method of determining the responsiveness of a patient with COPD to therapy which comprises monitoring the concentration of soluble E-cadherin in samples of the patient's blood serum with time and determining the rate of change of extent of progression of the disease by reference to a correlation graph such as one which correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration eg. as shown in Figure 1.

We also provide a method of determining the responsiveness of a patient with COPD to therapy which comprises monitoring the concentration of soluble E-cadherin in samples of the patient's urine with time and determining the rate of change of extent of progression of the disease by reference to a correlation graph such as one which correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration eg. as shown in Figure 2.

For greater confidence, the method may comprise monitoring the concentration of soluble E-cadherin in samples of the patient's urine and blood serum with time and determining the rate of change of extent of progression of the disease by reference to a correlation graph for each such as one which correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration eg. as shown in Figures 1 and 2.

As a further aspect of the invention we provide a product for prognosis of COPD severity in a patient which comprises means to report the concentration of soluble E-cadherin in a sample of blood serum taken from the patient.

We also provide a product for the prognosis of COPD severity in a patient which comprises means to report the concentration of soluble E-cadherin in a sample of urine taken from the patient.

We also provide use of means to report the concentration of soluble E-cadherin in a sample of a patient's urine in the manufacture of a prognostic product for determination of COPD disease severity in a patient.

We also provide use of means to report the concentration of soluble E-cadherin in a sample of a patient's blood serum in the manufacture of a prognostic product for determination of COPD disease severity in a patient.

For blood serum analysis, a 20-30μl volume of blood taken from a 'pin-prick' would be suitable and for urine analysis a sample of approximately 1ml taken "mid-flow" would be suitable.

Means to report the concentration of soluble E-cadherin in a sample of blood serum or urine preferably comprises an anti-soluble E-cadherin antibody.

For example, sE-cadherin concentration may be measured using a commercially available kit from Takara. This kit allows the measurement of sE-cadherin, using standard ELISA technology and the standard curve provided, which allows interpretation of the measurement in terms of a concentration.

Example 1

Blood serum, urine and induced sputum from 4 patient groups (healthy non-smokers, healthy smokers, asthmatics and COPD patients) were sampled and the soluble E-cadherin concentration in each body fluid was measured.

FEV1 was measured using the method given above. Predicted (normal) FEV1 was calculated for each patient in accordance with the algorithm given in the above mentioned Morris et al (1971) paper and the actual FEV1 given as a percentage of predicted.

Table 1 contains information relating to all patients used in this example.

Pack years refers to the level of smoke exposure. One pack year equates to 20 cigarettes smoked per day for 1 year.

The medicaments used in the table refer to 'salb': salbutamol and 'atro': Atrovent (ipratropium bromide).

The results are shown in the following Figures:

Figure 1 - FEV1 (as a percentage of the predicted value) as a function of concentration of soluble E-cadherin in blood serum

Figure 2 - FEV1 (as a percentage of the predicted value) as a function of concentration of soluble E-cadherin in urine.

The predicted value of FEV1 was determined according to Morris JF et al 1971: Am Rev Resp Dis **103,** 57-67.

The results presented in Figure 1 show that FEV1 (as a percentage of the predicted value) (y) is correlated with concentration of soluble E-cadherin in blood serum (x) in COPD patients according to Spearman's rank correlation analysis.

The correlation coefficient and p-values for the 4 patient groups from these data are as follows:

	Corr coeff	p-value
Healthy non-smokers	-0.36	0.521
Healthy smokers	-0.23	0.307
Asthmatics	0.02	0.946
COPD patients	0.67	0.033

The results presented in Figure 2 show that FEV1 (as a percentage of the predicted value) (y) is correlated with concentration of soluble E-cadherin in urine (x) in COPD patients according to Spearman's rank correlation analysis.

The correlation coefficient and p-values for the 4 patient groups from these data are as follows:

	Corr. coeff.	p-value
COPD	-0.66	0.038
Healthy Smokers	-0.76	0.016
Healthy Non-Smokers	-0.57	0.088
Asthma	-0.11	0.761

Both Figures 1 and 2 show that there is no correlation between FEV1 and concentration of soluble E-cadherin in urine or blood serum in asthmatics.

Claims

1. A method of determining the severity of Chronic Obstructive Pulmonary Disease (COPD) in a patient which comprises measuring the concentration of soluble E-cadherin in a sample of the patient's urine and/or blood serum and determining the extent of severity by reference to a correlation graph which correlates Forced Expiratory Volume in the first second of expiration (FEV1) with soluble E-cadherin concentration.

2. A method according to claim 1 comprising measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum.

3. A method according to claim 1 comprising measuring the concentration of soluble E-cadherin in a sample of the patient's urine.

4. A method according to claims 1 and 2 which comprises measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum and urine.

5. A method of treating a patient suffering from COPD which comprises determing the extent of the disease by identifying the levels of soluble E-cadherin in a sample of the patient's blood serum and/or urine followed by administration of a compound which ameliorates the symptoms of the disease.

6. A method according to claim 5 comprising identifying the concentration of soluble E-cadherin in a sample of the patient's blood serum.

7. A method according to claim 5 comprising identifying the concentration of soluble E-cadherin in a sample of the patient's urine.

8. A method according to claim 5 comprising identifying the levels of soluble E-cadherin in a sample of the patient's blood serum and urine.

9. A method of determing the responsiveness of a patient with COPD to therapy which comprises monitoring the concentration of soluble E-cadherin in a sample of the patient's blood serum and/or urine with time and determing the rate of change of extent of progression of the disease by reference to a correlation graph which correlates FEV1 with soluble E-cadherin concentration.

10. A method according to claim 9 comprising monitoring the concentration of soluble E-cadherin in a sample of the patient's urine.

11. A method according to claim 9 comprising monitoring the concentration of soluble E-cadherin in a sample of the patient's blood serum.

12. A method according to claim 9 comprising monitoring the concentration of soluble E-cadherin in samples of the patient's urine and blood serum with time.

13. A product for the prognosis of COPD severity in a patient which comprises means to report the concentration of soluble E-cadherin in a sample of blood serum and/or a sample of urine taken from the patient and a correlation graph which correlates FEV1 with solube E-cadherin concentration.

14. A product according to claim 13 wherein means to report the concentration of soluble E-cadherin comprises an anti-solube E-cadherin antibody.

15. A method according to any one of claims 1 to 12 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

TABLE. 1

Patient Group		Mean [sE-cadherin] in sputum supernatant (ng/ml)	Mean [sE-cadherin] in serum (ng/ml)	Mean [sE-cadherin] in urine (ng/ml)	Mean [IL-8]	Mean [Creatinine] (mmol/L)	[Urine]/ [Creatinine] ratio	Age of patient	Sex of patient	Medication taken by patient	Pack Years	FEV1 % pred
COPD	1	294	5082	1795	5049	8.1	222	59	F	nil	35	60
COPD	2	94	4728	1518	10661	1.3	1168	66	M	salb, atro	44	66.2
COPD	3	810	6239	1900	3218	4.7	404	48	M	nil	30	64.5
COPD	4	71	7297	255	3598	0.6	425	45	M	nil	30	75
COPD	5	830	5342	3066	548	17.5	175	47	M	atro	25 (ex)	41
COPD	6	1749	6781	3603	4809	12.4	291	43	M	nil	30	69
COPD	7	179	5208	996	15397	3.2	311	45	F	nil	30	67.1
COPD	8	821	1761	5617	14056	10.9	515	54	M	nil	40	23
COPD	9	815	5198	2340	11147	2.8	836	56	F	nil	40	40.4
COPD	10	658	2736	5034	2954	12.3	409	65	M	salb, atro	30 (ex)	54
Mean values of Patient Group		632	5037	2612	7144	7.4	476	53	7 M	-	35	56

Patient Group		Mean [sE-cadherin] in sputum supernatant (ng/ml)	Mean [sE-cadherin] in serum (ng/ml)	Mean [sE-cadherin] in urine (ng/ml)	Mean [IL-8]	Mean [Creatinine] (mmol/L)	[Urine]/ [Creatinine] ratio	Age of patient	Sex of patient	Medication taken by patient	Pack Years	FEV1 % pred
Healthy Smokers	1	506	5612	1775	827	9.4	189	42	F	nil	15	93
Healthy Smokers	2	547	5740	4568	221	15	304	42	F	nil	22	92
Healthy Smokers	3	376	4830	4310	796	17.5	246	38	F	nil	10	98
Healthy Smokers	4	463	5590	2609	716	4.4	593	35	F	nil	15	100
Healthy Smokers	5	446	5103	-	544	-	-	48	F	nil	20	90
Healthy Smokers	6	837	4733	878	461	16	55	26	F	nil	10	101
Healthy Smokers	7	1671	2761	780	3362	3.5	223	24	F	nil	11	105
Healthy Smokers	8	697	4856	1956	673	7	279	33	F	nil	15	98
Healthy Smokers	9	368	5585	1684	393	12.8	132	28	M	nil	10	109
Healthy Smokers	10	403	3431	9558	425	12.7	753	38	F	nil	20	93
Mean values of Patient Group		516	4824	3270	562	11.4	312	35	1 M	-	14.8	98

Patient Group		Mean [sE-cadherin] in sputum supernatant (ng/ml)	Mean [sE-cadherin] in serum (ng/ml)	Mean [sE-cadherin] in urine (ng/ml)	Mean [IL-8]	Mean [Creatinine] (mmol/L)	[Urine]/ [Creatinine] ratio	Age of patient	Sex of patient	Medication taken by patient	Pack Years	FEV1 % pred
Healthy Non-Smokers	1	673	5951	842	704	7.4	114	28	F	nil	nil	101
Healthy Non-Smokers	2	1006	7463	3976	179	15	265	41	F	nil	nil	96
Healthy Non-Smokers	3	654	2617	750	547	3	250	28	F	nil	nil	99.4
Healthy Non-Smokers	4	538	4697	2737	603	8	342	31	F	nil	nil	97
Healthy Non-Smokers	5	1118	6804	4022	206	17.3	232	33	F	nil	nil	83
Healthy Non-Smokers	6	367	3544	3329	337	11.2	297	21	F	nil	nil	104
Healthy Non-Smokers	7	782	8697	4639	667	12.4	374	52	F	nil	nil	100
Healthy Non-Smokers	8	673	7357	4918	347	11.5	428	47	F	nil	nil	95
Healthy Non-Smokers	9	976	4041	4963	683	8.5	584	43	F	nil	nil	84
Healthy Non-Smokers	10	1375	6094	2199	584	20	110	28	F	nil	nil	99.4
Mean values of Patient Group		816	5726	3237	486	11.4	300	35	0 M	-	-	95.9

Patient Group		Mean [sE-cadherin] in sputum supernatant (ng/ml)	Mean [sE-cadherin] in serum (ng/ml)	Mean [sE-cadherin] in urine (ng/ml)	Mean [IL-8]	Mean [Creatinine] (mmol/L)	[Urine]/ [Creatinine] ratio	Age of patient	Sex of patient	Medication taken by patient	Pack Years	FEV1 % pred
Asthma	1	334	5041	4900	753	13.7	358	39	M	salb	nil	101
Asthma	2	508	2027	3464	48	23	151	30	M	salb	nil	98
Asthma	3	240	6153	1817	73	7.1	256	22	F	salb	nil	89
Asthma	4	348	4168	1190	37	4.1	290	41	F	salb	nil	95
Asthma	5	577	5403	2228	528	10.3	216	27	M	salb	nil	94
Asthma	6	584	4625	4003	539	11	364	27	M	salb	nil	92
Asthma	7	320	5101	3406	285	16.7	204	33	F	salb	nil	84
Asthma	8	324	6190	320	496	-	-	40	F	salb	nil	98
Asthma	9	1767	4044	8039	2070	6.4	1256	37	M	salb	nil	89
Asthma	10	693	6038	2034	125	8.5	239	21	F	salb	Nil	98
Mean values of Patient Group		436	4879	3140	320	11.2	370	32	5 M	-	-	94

FIG. 1


Soluble E Cadherin in Serum Samples from 4 Patient Groups
COPD Patients
Healthy Smokers
Non smokers
Asthmaitcs
FEV1 % predict
120
100
80
60
40
20
2000
4000
6000
8000
10000
Serum (ng/ml)

FIG. 2

Soluble E Cadherin in Urine samples from 4 Patient Groups



Docket No.: PG3672 PCT/GB00/02015

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

DIAGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

the specification of which (check one)

[ ] is attached hereto.

[X] was filed on 25 May 2000 as Serial No. PCT/GB00/02015
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9912534.6	GREAT BRITAIN	29 May 1999	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Edward Gimmi, GlaxoSmithKline, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-4478.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael Robert WEST

Inventor's Signature: M.R. West Date: 20 Feb '02

Residence: BUNTINGFORD, HERTFORDSHIRE, UNITED KINGDOM

Citizenship: BRITISH GBX

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939